Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
175K
-
Shares change
-
+16.1K
-
Total reported value, excl. options
-
$4.52M
-
Value change
-
+$416K
-
Number of buys
-
3
-
Price
-
$25.87
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q3 2025
3 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q3 2025.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 175K shares
of 67.8M outstanding shares and own 0.26% of the company stock.
Largest 3 shareholders include Mirador Capital Partners LP (166K shares), Overbrook Management Corp (8.8K shares), and GAMMA Investing LLC (141 shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.